Peptide LibraryHexarelin (Examorelin)
Also known as: GHRP
Hexarelin (Examorelin), also called GHRP, is a research peptide in the Growth Hormone Secretagogue class. Hexarelin is a synthetic hexapeptide agonist at growth hormone secretagogue receptor 1a, structurally related to GHRP-6 and among the most potent releasers of growth hormone in the class.
For research use only.
Key Facts
- CAS
- 140703-51-1
- Molecular Weight (MW)
- 887.0 g/mol
- Half-life
- ~56–76 minutes (human PK studies)
- FDA status
- Not Approved
- Evidence level
- Limited Human Evidence
- Human dose established
- Yes
- Administration Route
- Intravenous
- Frequency
- Single doses in the published dose-response work
- Last updated
- Sep 6, 2026
- Reviewed
- Sep 5, 2026
- Targets
- GHSR
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Oct 2026 and Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 14
- Listed offers
- 17
- Median price per mg
- $9.65/mg
- Typical $7.87–$12.40/mg
Research summary
Potent GHRP (examorelin) that raises GH and can desensitize with frequent use. Also studied for cardiac GHSR effects. Not FDA-approved. WADA S2.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studies1 reviewed source
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Hexarelin (Examorelin) profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Hexarelin (Examorelin) dosage evidence
Hexarelin has a published human dose-response study: intravenous doses from 0 to 1.0 mcg/kg in healthy adult men, with the growth hormone response reaching a plateau at 1.0 mcg/kg. That study also measured cortisol and prolactin release, which is the finding most often left out when hexarelin is discussed. No product is approved and no repeated-dosing regimen is established.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 0.125–1.0 mcg/kg intravenously (weight-based) |
| Route | Intravenous |
| Frequency | Single doses in the published dose-response work |
| Duration studied | Acute pharmacology protocol |
| Evidence level | Limited Human Evidence |
| Last reviewed | 2026-09-05 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Dose-response study in healthy men (1996)Clinical trial · Human dose-response pharmacology study | Healthy adult males | 0 to 1.0 mcg/kg; plateau GH response at 1.0 mcg/kg; 0.125 mcg/kg used as the low dose in combination with GHRH(1-29)-NH2 1.0 mcg/kg | Intravenous | Single dose per level | Acute | Growth hormone, cortisol and prolactin release | Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study. J Clin Endocrinol Metab. 1996. |
Where sources disagree
- Published human dosing is weight-based and intravenous — 1.0 mcg/kg is roughly 70 mcg for a 70 kg adult. Hexarelin is sold with fixed subcutaneous protocols commonly quoted at 100–200 mcg two or three times daily, which is both a higher dose and a different route from anything published.
- The same dose-response study that established hexarelin's growth hormone effect also reported cortisol and prolactin release. Secondary sources routinely cite the growth hormone finding and omit the other two, which come from the identical experiment.
- The published work is acute and single-dose. Desensitisation with repeated administration is a recognised issue for growth hormone secretagogues and is not addressed by a single-dose study.
Reconstitution
Common research vial sizes: 2 mg, 5 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 2 mg | 2 mL | 1 mg/mL | 10 mcg per 0.01 mL |
| 5 mg | 2 mL | 2.5 mg/mL | 25 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Sequence & molecular data
| Molecular formula | C47H58N12O6 |
|---|---|
| Molecular weight | 887.0 g/mol |
| CAS number | 140703-51-1 |
| Half-life | ~56–76 minutes (human PK studies) |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
| PubChem CID | 6918297 |
| FDA UNII | 09QF37C617 |
| ChEMBL | CHEMBL108335 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Hexarelin is a synthetic hexapeptide agonist at growth hormone secretagogue receptor 1a, structurally related to GHRP-6 and among the most potent releasers of growth hormone in the class. A distinguishing feature is desensitisation: the growth hormone response attenuates markedly with repeated dosing over days to weeks, more so than with other secretagogues. It also binds CD36, a scavenger receptor expressed in cardiac tissue, and cardiovascular effects observed in animal models have been attributed to that interaction rather than to growth hormone release, making it a subject of study independent of the somatotropic axis.
Origin
Synthetic hexapeptide GHRP.
Targets
Studies
- The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity
- The cardiovascular action of hexarelin
- Interaction of the growth hormone releasing peptide hexarelin with somatostatin
- Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry
- Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway
Research statistics
289 PubMed publications · 35.2% human clinical research · 0 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Hexarelin (Examorelin) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
Hexarelin (Examorelin) side effects
Hexarelin (Examorelin) has only limited human data, so the list below is incomplete and its side-effect profile is not well established.
Side Effects
- Cortisol/prolactin rise
- Hunger
- Desensitization
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Hexarelin (Examorelin): frequently asked questions
What is Hexarelin (Examorelin)?
Potent GHRP (examorelin) that raises GH and can desensitize with frequent use. Also studied for cardiac GHSR effects. Not FDA-approved. WADA S2.
How does Hexarelin (Examorelin) work?
Hexarelin is a synthetic hexapeptide agonist at growth hormone secretagogue receptor 1a, structurally related to GHRP-6 and among the most potent releasers of growth hormone in the class. A distinguishing feature is desensitisation: the growth hormone response attenuates markedly with repeated dosing over days to weeks, more so than with other secretagogues.
Is Hexarelin (Examorelin) FDA approved?
No. Hexarelin (Examorelin) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Hexarelin (Examorelin)?
Reported half-life for Hexarelin (Examorelin) is ~56–76 minutes (human PK studies). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is Hexarelin (Examorelin) banned in sport?
Hexarelin (Examorelin) is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
What peptides are similar to Hexarelin (Examorelin)?
Compounds most often compared with Hexarelin (Examorelin) include Ipamorelin, GHRP-6, GHRP-1 and Pralmorelin (GHRP-2). They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- WADA Prohibited List 2026External reference
- The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity — Clin Endocrinol (Oxf), 1996External reference
- The cardiovascular action of hexarelin — J Geriatr Cardiol, 2014External reference
- Interaction of the growth hormone releasing peptide hexarelin with somatostatin — Clin Endocrinol (Oxf), 1997External reference
- Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry — J Anal Toxicol, 2025External reference
- Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway — Eur J Med Res, 2023External reference
Related research, comparisons & guides
- Ipamorelin Side Effects: What Selectivity Actually Removes
- Hexarelin: The Most Potent GHRP, and Why That Is Not Simply Good
- MK-677 (Ibutamoren): An Oral Secretagogue That Is Not a Peptide
- Peptide dosage chart: dose, route and frequencyCategory
- Hexarelin (Examorelin) calculator: reconstitution and syringe units
- How to store peptides before and after reconstitution
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Sep 6, 2026 · Version 3
This Hexarelin (Examorelin) profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Hexarelin (Examorelin) research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →